Role of yavadi upanaha as add on therapy with kanchnara guggulu and varuna kwatha in stanagranthi wsr fibroadenoma

A RANDOMIZED OPEN LABELLED COMPARATIVE CLINICAL STUDY ON THE EFFICACY OF YAVADI UPANAHA AS ADD ON THERAPY WITH KANCHANARA GUGGULU AND VARUNA KWATHA IN THE MANAGEMENT OF STANA GRANTHI WITH SPECIAL REFERANCE TO FIBROADENOMA - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/108023

Enrollment

Registered

2026-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D249- Benign neoplasm of unspecified breast

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Female patient within the age group of 18-50 years Participants irrespective of marital status and parit Participants presenting the classical symptoms like MruduChala AlparujaShopha Participants with symptoms of fibroadenoma Palpable breast lump consistent with fibroadenoma on clinical examination mobile well circumcised firm or rubbery non-tender A lump with or without pain Mammography findings fibroadenoma over well defined, hypoechoic mass in sonomammograph Size of lesion less than or equal to 2 cm for observation Non suspicious feature (BIRADS-0,1 and 2)

Exclusion criteria

Exclusion criteria: Subjects who are pregnant and lactating mothers. Suspicion of malignancy on clinical or imaging findings. Irregular poorly, hard fixed, defined mass. Skin dimpling, nipple retraction. Nipple discharge in one or both breast. BIRADS 3,4 and 5 on imaging. Subjects with giant and juvenile fibroadenoma with h/o breast malignancy/surgery. Subjects with breast implants in the target breast. Subjects with breast cyst within fibroadenoma, mastitis, phylloids tumor, breast abscess. Subjects participating in another clinical trial involving investigational drug device.

Design outcomes

Primary

Measure	Time frame
1)Change in volume of fibroadenoma -Fibroadenoma volume will be measured by Sonomammagraphy Baseline is 2 months Follow up after 3 months 2)Size of fibroadenomaFibroadenoma will be assessed by physical examination including measurement of tumor size at clinical visits. 3)Patient reported outcomes Secondary outcome Outcome MeasureMeasure Description Time Frame Incidence of adverse events Incidence of rash, itching etc-Upto 2 months Timepoint: Baseline 2 months follow up after 3 months	—

Measure

Time frame

1)Change in volume of fibroadenoma -Fibroadenoma volume will be measured by Sonomammagraphy Baseline is 2 months Follow up after 3 months 2)Size of fibroadenomaFibroadenoma will be assessed by physical examination including measurement of tumor size at clinical visits. 3)Patient reported outcomes Secondary outcome Outcome MeasureMeasure Description Time Frame Incidence of adverse events Incidence of rash, itching etc-Upto 2 months Timepoint: Baseline 2 months follow up after 3 months

—

Secondary

Measure	Time frame
Patient reported outcomes Patient rated pain and patient responses to satisfaction questionnaire will be measured at intervals up to 2 months. Up to 3 months Secondary outcome Outcome Measure Measure Description Time Frame Incidence of adverse events Incidence of rash, itching etc-Upto 2 months Timepoint: total study duration-60 days Pre assessment 0th day 1st assessment 60 th day Follow up 90 th day	—

Measure

Time frame

Patient reported outcomes Patient rated pain and patient responses to satisfaction questionnaire will be measured at intervals up to 2 months. Up to 3 months Secondary outcome Outcome Measure Measure Description Time Frame Incidence of adverse events Incidence of rash, itching etc-Upto 2 months Timepoint: total study duration-60 days Pre assessment 0th day 1st assessment 60 th day Follow up 90 th day

—

Countries

India

Contacts

Public ContactDr Mayuri kailas dhoran

Sri Sri College of Ayurvedic Science and Research

dr.rachanabhat@gmail.com9535744077

Outcome results